Advanced in Ovarian Cancer

Dr. Joshua C. Lukenbill

Oncology | Hematology | Hematology Oncology

St Anthony Regional Hospital And Nursing Home

311 S Clark St,

Carroll, IA

Clinical Trials:Currently Recruiting for 21 Trials

Accepting New Patients

Offers Telehealth

Advanced in Ovarian Cancer

St Anthony Regional Hospital And Nursing Home

311 S Clark St,

Carroll, IA

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joshua Lukenbill is an Oncologist and a Hematologist in Carroll, Iowa. Dr. Lukenbill is rated as an Advanced provider by MediFind in the treatment of Ovarian Cancer. His top areas of expertise are Lung Cancer, Multiple Myeloma, Glioma, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Lukenbill is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 121 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 5 clinical trials in the study of Ovarian Cancer.

Specialties

Oncology

Hematology

Hematology Oncology

Licenses

Internal Medicine in IA

Hospital Affiliations

St Anthony Regional Hospital & Nursing Home

University Of Iowa Hospital & Clinics

Unitypoint Health - Des Moines Iowa Methodist Medi

Mercyone Des Moines Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem BCBS

Blue Cross Blue Shield

Change Healthcare

OTHER MEDICARE
OTHER MEDICARE PART D

Cigna

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners

Highmark

Humana

HMO
INDEMNITY
POS
PPO

Independent Health

Managed Medicaid

OTHER MANAGED MEDICAID

Medica

Medicaid

OTHER MEDICAID
STATE MEDICAID

Medicare

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE PART D

Northern Plains Alliance

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE PDP

Oscar

TeamCare

OTHER COMMERCIAL

UnitedHealthcare

Walgreens

MEDICARE DISCOUNT CARD
MEDICARE PDP
OTHER MEDICARE

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

Wellmark

View 17 Less Insurance Carriers -

Locations

ST ANTHONY REGIONAL HOSPITAL AND NURSING HOME
311 S Clark St, Carroll, IA 51401

Call: 712-792-3581

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

118 Clinical Trials

Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide

Study Phase: Phase 2/Phase 3

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium

Study Phase: Phase 3

Cancer Moonshot Biobank Research Protocol

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Other

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Procedure

Study Drug: Olaparib

Study Phase: Phase 2

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological

Study Drugs: Bevacizumab, Osimertinib

Study Phase: Phase 3

A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Radiation, Biological

Study Drugs: Carboplatin, Cisplatin, Pembrolizumab

Study Phase: Phase 2

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Radiation, Drug

Study Drug: Atezolizumab

Study Phase: Phase 2/Phase 3

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological, Drug, Other

Study Drugs: Obinutuzumab, Venetoclax

Study Phase: Phase 3

A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological

Study Drugs: Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Paclitaxel

Study Phase: Phase 3

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

Enrollment Status: Recruiting

Publish Date: February 10, 2026

Intervention Type: Drug, Other

Study Phase: Phase 3

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Enrollment Status: Recruiting

Publish Date: February 04, 2026

Intervention Type: Procedure, Other

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

Enrollment Status: Recruiting

Publish Date: February 04, 2026

Intervention Type: Other, Behavioral

Study Phase: Phase 3

A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

Enrollment Status: Recruiting

Publish Date: February 04, 2026

Intervention Type: Procedure, Drug, Biological, Other

Study Drugs: Gemcitabine, Cisplatin, Pegfilgrastim

Study Phase: Phase 2

Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

Enrollment Status: Recruiting

Publish Date: February 02, 2026

Intervention Type: Procedure, Biological, Drug

Study Drugs: Lenalidomide, Methotrexate, Nivolumab, Rituximab

Study Phase: Phase 1

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Enrollment Status: Recruiting

Publish Date: January 26, 2026

Intervention Type: Other

Study Phase: Not Applicable

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

Enrollment Status: Recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Biological, Drug

Study Drugs: Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide

Study Phase: Phase 3

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Enrollment Status: Recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Biological, Drug

Study Drugs: Daratumumab, Dexamethasone, Lenalidomide

Study Phase: Phase 3

Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy

Enrollment Status: Recruiting

Publish Date: January 14, 2026

Intervention Type: Other, Procedure, Drug, Radiation

Study Drugs: Abiraterone acetate, Apalutamide, Hormone therapy, Prednisone

Study Phase: Phase 3

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Enrollment Status: Recruiting

Publish Date: January 14, 2026

Intervention Type: Drug, Radiation

Study Drugs: Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Relugolix, Triptorelin

Study Phase: Phase 3

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Enrollment Status: Recruiting

Publish Date: January 14, 2026

Intervention Type: Other, Procedure, Radiation

Study Phase: Phase 3

Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin

Enrollment Status: Recruiting

Publish Date: January 14, 2026

Intervention Type: Drug, Procedure

Study Phase: Phase 1

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological, Radiation, Other

Study Drugs: Cisplatin, Nivolumab

Study Phase: Phase 3

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug

Study Drugs: Atezolizumab, Talazoparib

Study Phase: Phase 2

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological

Study Drugs: Olaparib, Pembrolizumab

Study Phase: Phase 2

A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Biological, Drug

Study Drugs: Carboplatin, Nivolumab, Paclitaxel

Study Phase: Phase 3

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Biological, Procedure

Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate

Study Phase: Phase 2

A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements

Enrollment Status: Suspended

Publish Date: February 12, 2026

Intervention Type: Drug, Biological, Procedure, Other

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Oral Azacitidine, Prednisone, Rituximab, Vincristine Sulfate

Study Phase: Phase 2/Phase 3

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Procedure, Radiation, Other

Study Drug: Olaparib

Study Phase: Phase 2

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug, Radiation

Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C

Study Phase: Phase 3

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Biological

Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium

Study Phase: Phase 3

A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological

Study Drugs: Atezolizumab, Bevacizumab, Carboplatin, Cetuximab, Cisplatin, Docetaxel

Study Phase: Phase 2/Phase 3

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug

Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 2

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: February 11, 2026

Intervention Type: Drug

Study Drugs: Capecitabine, Carboplatin, Cisplatin

Study Phase: Phase 3

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 10, 2026

Intervention Type: Drug, Other

Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate

Study Phase: Phase 3

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Enrollment Status: Suspended

Publish Date: February 05, 2026

Intervention Type: Biological, Drug, Procedure, Other

Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab

Study Phase: Phase 3

Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)

Enrollment Status: Active_not_recruiting

Publish Date: February 05, 2026

Intervention Type: Drug

Study Drugs: Avelumab, Cetuximab

Study Phase: Phase 2

CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 05, 2026

Intervention Type: Other, Drug

Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix

Study Phase: Phase 3

Genomically-Guided Treatment Trial in Brain Metastases

Enrollment Status: Suspended

Publish Date: February 04, 2026

Intervention Type: Drug

Study Drugs: Abemaciclib, Paxalisib, Entrectinib

Study Phase: Phase 2

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Enrollment Status: Active_not_recruiting

Publish Date: February 02, 2026

Intervention Type: Other, Procedure, Drug

Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 3

A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers

Enrollment Status: Active_not_recruiting

Publish Date: January 28, 2026

Intervention Type: Other, Drug

Study Drug: Sinecatechins

Study Phase: Phase 2

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Drug

Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine

Study Phase: Phase 2/Phase 3

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Procedure, Drug, Radiation

Study Drugs: Capecitabine, Fluorouracil, Mitomycin

Study Phase: Phase 2

A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Drug

Study Drugs: Darolutamide, Goserelin acetate, Leuprolide acetate, Triptorelin

Study Phase: Phase 3

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Procedure, Biological, Drug, Radiation

Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine

Study Phase: Phase 2

Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

Enrollment Status: Active_not_recruiting

Publish Date: January 22, 2026

Intervention Type: Drug, Radiation

Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine

Study Phase: Phase 3

Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Enrollment Status: Suspended

Publish Date: January 14, 2026

Intervention Type: Other, Procedure, Drug, Radiation

Study Drug: Cisplatin

Study Phase: Phase 2/Phase 3

View 29 Less Clinical Trials

6 Total Publications

Acupuncture for Chronic Radiation-Induced Xerostomia in Head and Neck Cancer: A Multicenter Randomized Clinical Trial.

Journal: JAMA network open

Published: May 13, 2024

View All 6 Publications

Similar Doctors

Advanced in Ovarian Cancer

Dr. Robert J. Behrens

Oncology | Hematology | Hematology Oncology

Advanced in Ovarian Cancer

Dr. Robert J. Behrens

Oncology | Hematology | Hematology Oncology

St Anthony Regional Hospital And Nursing Home

311 S Clark St, St Anthony Chronic Care Cl,

Carroll, IA

(0.1 miles away)

712-794-5402

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Robert Behrens is an Oncologist and a Hematologist in Carroll, Iowa. Dr. Behrens is rated as a Distinguished provider by MediFind in the treatment of Ovarian Cancer. His top areas of expertise are Colorectal Cancer, Lung Cancer, Febrile Neutropenia, Bone Marrow Aspiration, and Colonoscopy. Dr. Behrens is currently accepting new patients.

Experienced in Ovarian Cancer

Dr. Seema Harichand-Herdt

Hematology Oncology | Oncology | Hematology

Experienced in Ovarian Cancer

Dr. Seema Harichand-Herdt

Hematology Oncology | Oncology | Hematology

Cass County Memorial Hospital

1501 E 10th St,

Atlantic, IA

(45.7 miles away)

712-243-3250

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Seema Harichand-Herdt is a Hematologist Oncology specialist and an Oncologist in Atlantic, Iowa. Dr. Harichand-Herdt is rated as a Distinguished provider by MediFind in the treatment of Ovarian Cancer. Her top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Anal Cancer, Bone Marrow Aspiration, and Gastrostomy. Dr. Harichand-Herdt is currently accepting new patients.

VIEW MORE OVARIAN CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lukenbill's expertise for a condition

ConditionClose